DUPONT-MERCK RECONSIDERING DISCONTINUATION OF UNIT-DOSE PACKS
DUPONT-MERCK RECONSIDERING DISCONTINUATION OF UNIT-DOSE PACKS of Coumadin, Percodan, Percocet and Symmetrel following discussions with the American Society of Hospital Pharmacists. DuPont-Merck said Feb. 23 that at the request of ASHP it is re- examining the decision to discontinue the unit-dose packs, which the company announced in October as being one of a series of cost- cutting initiatives ("The Pink Sheet" Nov. 8, 1993, T&G-1).
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth